Reproductive Potential of Patients With CML Receiving A TKI — Part 1
Chapter 3In this video, Jane Apperley, MBChB, MD, FRCP, FRCPath, professor of medicine and chair of the department of haematology at Imperial College London in England, discusses the reproduction potential of male and female patients with chronic myeloid leukemia being treated with a tyrosine kinase inhibitor.
Ponatinib for Chronic Myeloid Leukemia — Part 1
In this video, Jane Apperley, MBChB, MD, FRCP, FRCPath, professor of medicine and chair of the department of haematology at Imperial College London in England, discusses research into ponatinib for chronic myeloid leukemia that was presented at the 2017 American Society of Clinical Oncology (ASCO) meeting.
Ponatinib for Chronic Myeloid Leukemia — Part 2
In this video, Jane Apperley, MBChB, MD, FRCP, FRCPath, professor of medicine and chair of the department of haematology at Imperial College London in England, discusses some benefits associated with ponatinib among patients with chronic myeloid leukemia.
Reproductive Potential of Patients With CML Receiving A TKI — Part 2
In this video, Jane Apperley, MBChB, MD, FRCP, FRCPath, professor of medicine and chair of the department of haematology at Imperial College London in England, discusses the subjectivity of tyrosine kinase inhibitor treatment among women with chronic myeloid leukemia who are of reproductive potential.
